Do Analysts Recommend CVS at $67.06?

CVS Health stock is trading -25.62% below its average target price of $90.16 after marking a 1.2% during today's morning session. Analysts are giving the large-cap Pharmaceutical Retail company an average rating of buy and target prices ranging from $76.0 to $110.0 per share.

CVS Health's short interest — meaning the percentage of the share float that is being shorted — is lower than average at 1.1%. The stock's short ratio is 1.96. The company's insiders own 0.18% of its outstanding shares, which indicates a strong alignment between management and shareholder interests.

Another number to watch is the company's rate of institutional share ownership, which now stands at 79.9%. In conclusion, we believe there is mixed market sentiment regarding CVS Health.

Institutions Invested in CVS Health

Date Reported Holder Percentage Shares Value
2023-06-30 Vanguard Group Inc 9% 116,676,882 $7,824,351,422
2023-06-30 Blackrock Inc. 7% 93,734,850 $6,285,858,812
2023-06-30 State Street Corporation 4% 55,877,387 $3,747,137,435
2023-06-30 Morgan Stanley 3% 33,253,424 $2,229,974,532
2023-06-30 Capital World Investors 2% 30,490,802 $2,044,713,107
2023-06-30 Geode Capital Management, LLC 2% 23,325,287 $1,564,193,689
2023-06-30 FMR, LLC 2% 21,292,797 $1,427,894,914
2023-06-30 Invesco Ltd. 1% 17,002,487 $1,140,186,736
2023-06-30 Bank of America Corporation 1% 16,551,119 $1,109,917,999
2023-06-30 Dodge & Cox Inc 1% 16,024,422 $1,074,597,700
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.